Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2022 08:30 ET | Source: Palisade Bio, Inc.

Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study Newsoara to fully fund Phase...
February 08, 2022 08:00 ET | Source: Palisade Bio, Inc.

Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting

CARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
November 15, 2021 09:55 ET | Source: Zenith Capital Corp.

Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment

CALGARY, Alberta, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics”), a wholly-owned subsidiary of...
September 21, 2021 08:00 ET | Source: Zenith Capital Corp.

Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study

CALGARY, Alberta, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) and Newsoara BioPharma Co., Ltd. (“Newsoara”) announced today the initiation of a...
July 29, 2021 08:15 ET | Source: Palisade Bio, Inc.

Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery

Statistically significant 1.1-day acceleration in return of bowel function Favorable overall safety profile in 120 patients CARLSBAD, Calif. and SHANGHAI, China, July 29, 2021 (GLOBE NEWSWIRE) --...